Table 1. Patient disposition for each... | American Society of Hematology

Table 1.

Patient disposition for each study age group in the ITT and safety-evaluable populations of the POLARIX study

Study population, n	Patients aged ≥60 y n = 629 (ITT) n = 623 (safety)		Patients aged ≥65 y n = 467 (ITT) n = 462 (safety)		Patients aged ≥70 y n = 284 (ITT) n = 280 (safety)		Patients aged ≥75 y n = 120 (ITT) n = 117 (safety)
Study population, n	Pola-R-CHP	R-CHOP	Pola-R-CHP	R-CHOP	Pola-R-CHP	R-CHOP	Pola-R-CHP	R-CHOP
ITT	311	318	231	236	141	143	60	60
Safety evaluable	306	317	227	235	137	143	57	60
PRO evaluable	291	299	215	221	130	131	54	56
FACT-LymS evaluable	286	291	210	213	126	128	51	55
EORTC QLQ-C30 evaluable	289	297	214	219	130	129	54	55

Study population, n	Patients aged ≥60 y n = 629 (ITT) n = 623 (safety)		Patients aged ≥65 y n = 467 (ITT) n = 462 (safety)		Patients aged ≥70 y n = 284 (ITT) n = 280 (safety)		Patients aged ≥75 y n = 120 (ITT) n = 117 (safety)
Study population, n	Pola-R-CHP	R-CHOP	Pola-R-CHP	R-CHOP	Pola-R-CHP	R-CHOP	Pola-R-CHP	R-CHOP
ITT	311	318	231	236	141	143	60	60
Safety evaluable	306	317	227	235	137	143	57	60
PRO evaluable	291	299	215	221	130	131	54	56
FACT-LymS evaluable	286	291	210	213	126	128	51	55
EORTC QLQ-C30 evaluable	289	297	214	219	130	129	54	55

ITT, intention-to-treat population; PRO, patient-reported outcomes.